SLC7A8 encodes a neutral amino acid transporter that forms a heterodimeric complex with SLC3A2 to facilitate the transport of amino acids across cell membranes 1. The protein functions as an antiporter, mediating bidirectional exchange of amino acids with asymmetric substrate affinities that allow regulation of intracellular amino acid pools. Beyond amino acid transport, SLC7A8 plays important roles in cellular uptake of various compounds including kynurenine, which is involved in immune regulation through the aryl hydrocarbon receptor pathway 12. In cancer contexts, SLC7A8 shows tissue-specific expression patterns and clinical relevance. The transporter is decreased in lung adenocarcinoma tissues compared to normal tissue, and its downregulation correlates with poor prognosis and altered immune cell infiltration 3. Conversely, in estrogen receptor-positive breast cancer, particularly low proliferative/luminal A subtypes, high SLC7A8 expression associates with favorable prognosis and longer survival 4. Functional studies demonstrate that SLC7A8 can transport doxorubicin, and genetic variants in SLC7A8 are associated with early disease progression in osteosarcoma patients receiving chemotherapy 5. Additionally, SLC7A8 knockout mice show protection against diet-induced obesity, suggesting metabolic regulatory functions 6.